business / news / / Benzinga
The weight loss drug maker reported first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the consensus of $11.13 billion.
Novo Nordisk first quarter sales reached $15.17 billion, significantly beating expectations of $11.13 billion.
KEY POINTS
- A reversal of 340B Drug Pricing Program provisions in the U.S. boosted both sales and reported profit.
- Wegovy pill prescriptions surpassed 200,000 weekly and totaled over 2 million since January launch.
- Novo Nordisk raised its 2026 sales guidance to $42.39 billion-$46.24 billion, above previous forecasts.
- Adjusted 2026 operating profit is now projected to decline 4%-12% at CER, excluding 340B provision impact.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →